AI image of a lung cross section
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

4D Medical’s (ASX:4DX) radioisotope-free CT:VQ lung scanning tech will form part of a U.S. Department of Defense-paid pilot leading into a formal FDA submission for approval. The company sees the chance to “displace the one million nuclear VQ scans performed each year… a billion dollar opportunity.”

4D Medical, which specialises in lung scanning technology, has a long-running history with the US DoD including former studies around veterans who had received lung damage from ‘burn pits’ – which are what they sound like.

As for its CT:VQ product capability announced in December, 4DX had been working toward a ‘safer’ way of imaging lungs, with a $1.9M grant secured to that end.

Under the pilot program announced on Monday, the DoD will not work with veterans but instead with active military personnel. The value proposition here for 4DX, in terms of the sheer size of the U.S. military membership, is fairly obvious.

“With over 200 military hospitals and clinics globally, the [Military Health Service] is tasked with providing high-quality, integrated healthcare to ensure the readiness and resilience of the U.S. Armed Forces,” the company reiterated.

Though, for now, it’s still small scale. Greater fruits will likely be borne if the ‘commercial pilot’ is deemed by DoD (or MHS) as a success. A total of 80 patients will form part of the first trial.

Of likely interest is 4DX’s CT:VQ scans allow for early detection of multiple lung conditions including CPOD and chronic thromboembolic hypertension.

“We are honoured to receive continued interest in the use of our technology from the DoD as a new pathway to enhance lung health outcomes for military personnel,” 4DX CEO Andreas Fouras said.

“CT:VQ is set to disrupt a billion-dollar segment of respiratory diagnostics by displacing Nuclear VQ imaging with a technology that is faster, safer, cheaper, more convenient and more accessible. We have been working for some time, leveraging hard-fought experience with existing products, to build an aggressive market adoption strategy.”

4DX last traded at 49.5cps.

Join the discussion: See what HotCopper users are saying about 4D Medical and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

4DX by the numbers
More From The Market Online
The Market Online Video

HotCopper Highlights, Week 50: 4DX above $2/sh, Nanoveu, Ovanti & more

Good Afternoon and welcome to HotCopper Highlights wrapping up Week 50 of the year, I’m Jon Davidson.

‘Potential is enormous’: GreenX likes what it’s found in Tannenberg, is activating acquisition option

GreenX Metals has activated an option to secure control of the Tannenberg Copper Project in Germany,…
The Market Online Video

ASX Market Open: Oz shares heading for W50 weekly gains with Friday rally | Dec 12

ASX today – The third-last week of CY25 may actually end on gains, with a late-on…

Listen: HotCopper Wire CY25 Wrapped – Looking back at Invictus, Kaili, DRO, and more

In the first half of the HotCopper Wire‘s CY25 end-of-year special, Isaac McIntyre and Jonathon Davidson look back over the year that was